IDEAYA Biosciences Inc IDE397 Phase 2 Monotherapy Expansion Dose Update Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Anupam Rama - J.P. Morgan Securities LLC - Analyst : Hey, guys. Thanks so much for taking the question and congrats on the update as well. So a quick question for me. When you look at the patients who had responses, anything in the baseline characteristics that would predict response and/or deeper tumor size reduction by line of therapy or otherwise? And then also we got an e-mail question is the SAM assay that you guys use a standard assay when you compare it to like what other companies have shown previously?

Question: Maury Raycroft - Jefferies LLC - Analyst : Good morning. Thanks for taking my question, and I'll add my congrats on the data as well. Let's see. I guess, based on the Phase 2 SAM reduction that you're seeing here with some of the deep SAM responses, what are your latest thoughts on how you anticipate MAT2A inhibitor should increase the PRMT5 therapeutic index? And how do these data influence your combo strategies?

Question: Maury Raycroft - Jefferies LLC - Analyst : Got it. That's helpful. And maybe one other question. Just wondering how many patients you've enrolled in this study. And you mentioned the registrational plan for 397 in 2025. Can you clarify if that will be as monotherapy or combo and what the objectives of that study will be?

Question: Omari Barut - Goldman Sachs & Co. LLC - Analyst : Good morning. This is Omari on for Corinne. So we had a question on the strategy on the cohort. And another question from me. So how does this data update inform your monotherapy development strategy, looking ahead? And then, is the monotherapy strategy taking on a higher priority from (technical difficulty)

Question: Yigal Nochomovitz - Citi Investment Research - Analyst : Thanks very much, and congrats again on the data you, Joe and team. Just a few questions for me. You showed the ctDNA molecular response. I'm curious if you had any notable correlations between the molecular response and the resist response. And similar question for the SAM pharmacodynamic reductions. But my understanding is that it may be harder to detect any correlations with the SAM biomarker. Thanks.

Question: Yigal Nochomovitz - Citi Investment Research - Analyst : Okay, thanks. And then, Yujiro, with respect to the combination strategy with 397, I recall some years ago, there were some chemo combos, I think, taxane and pemetrexed. Those weren't continued. What is your current thinking now in terms of what type of combinations you would pursue with 397? And seemingly, that would be at the 30 milligram dose. And then can you just clarify with the combo with 193 and Trodelvy, is that at 30 milligrams or potentially lower given the synergies in the dose escalation you're doing? Thanks.

Question: Yigal Nochomovitz - Citi Investment Research - Analyst : Okay. And then with regard to the comb -- the publication strategy -- the joint publication strategy with Amgen, any updates there as far as when we might see that in a print form? Thanks. without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated companies. JULY 08, 2024 / 12:00PM, IDYA.OQ - IDEAYA Biosciences Inc IDE397 Phase 2 Monotherapy Expansion Dose Update

Question: Ben Burnett - Stifel, Nicolaus & Company, Incorporated - Analyst : Great. Thank you, and congrats on these data. I just wanted to dive into the safety a bit. The safety profile that you're seeing, it looks quite clean. But as I understand, I think this program has been in the works for some time. So I guess, I was just wondering if you could maybe just kind of talk us through the range of doses tested and sort of the scope patient experience that you have? And really, just curious to see if you're -- are you seeing anything in the AE profile that would be meaningful to your ability to combine with either PRMT5 inhibitor or Trodelvy?

Question: Ben Burnett - Stifel, Nicolaus & Company, Incorporated - Analyst : Okay. That's very helpful. I appreciate that context. without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated companies. JULY 08, 2024 / 12:00PM, IDYA.OQ - IDEAYA Biosciences Inc IDE397 Phase 2 Monotherapy Expansion Dose Update Maybe I could just ask one more on just the biology that Dr. White was speaking to earlier. He talked about a couple of different pathways, sort of this three mRNA splicing pathway and this other kind of nucleotide access. I guess the question is, are both of these at play in any given cancer? Or certain cancers, you rely on one pathway kind of more than the other? Just trying to get a sense for kind of the underlying rationale for lung cancer with PRMT5 and sort of bladder for Trodelvy.

Question: Matthew Biegler - Oppenheimer & Co., Inc. - Analyst : Thanks for the questions. This is really impressive. I wanted to tag along the last question on the safety. i know you spoke a little bit about the heme tox or lack thereof. I wanted to ask about liver tox because that was another issue with Agios's MAT2A drug in the past. And Darrin, do you think that it's the drug selectivity for MAT2A versus MAT1A that might be kind of driving that better therapeutic window?

Question: Matthew Biegler - Oppenheimer & Co., Inc. - Analyst : I had another question that came in from an investor was -- a question on, were there any biopsies done in this protocol? And if yes, did you see any decrease in tumor SDMA?

Question: Jeet Mukherjee - BTIG LLC - Analyst : Hey. This is Jeet on for Justin, and thanks for taking the question. And once again, congrats on the data. So you talked about the rationale for 397 you use in squamous lung, but it also seems you have a signal in adenocarcinoma of the lung as well. Could you just expand on your thinking there between these subtypes and moving forward in the clinic? Thanks.

Question: Andrew Berens - Leerink Partners LLC - Analyst : Thanks for hosting the webcast. Just wanted to follow up on the [common] strategy for 397. Wondering about your dedications to Trodelvy in urothelial. I think it's been the least compelling of the ADCs in that disease so far, primarily limited by chemo-type toxicities. The population seem particularly sensitive too. Does your relationship with Gilead allow you to combine with other ADC like PADCEV? And if so, what would the hypothetical effects of using the adeno based payload be with 397 in terms of efficacy and toxicity?

Question: Andrew Berens - Leerink Partners LLC - Analyst : Okay. But you could consider using another ADC, a topo ADC other than? without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated companies. JULY 08, 2024 / 12:00PM, IDYA.OQ - IDEAYA Biosciences Inc IDE397 Phase 2 Monotherapy Expansion Dose Update

Question: Timothy Chiang - Capital One Securities, Inc. - Analyst : Hey, Yujiro. Solid data set. I think you've highlighted that you want to get into a registrational study next year. What do you need to do between now and then to get to that target?

Question: Timothy Chiang - Capital One Securities, Inc. - Analyst : And maybe just one follow-up, Yujiro. I mean, by middle of next year, we probably should be able to have some data in some of these combinations as well. Is that right? without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated companies. JULY 08, 2024 / 12:00PM, IDYA.OQ - IDEAYA Biosciences Inc IDE397 Phase 2 Monotherapy Expansion Dose Update

Question: Timothy Chiang - Capital One Securities, Inc. - Analyst : Yeah, like Amgen's PRMT5 combination with your MAT2A inhibitor?